These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 17722511

  • 1. Targeting nanomedicines in the treatment of Crohn's disease: focus on certolizumab pegol (CDP870).
    Dinesen L, Travis S.
    Int J Nanomedicine; 2007; 2(1):39-47. PubMed ID: 17722511
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Certolizumab pegol in Crohn's disease.
    Patel VK, Ghosh S.
    Drugs Today (Barc); 2008 Nov; 44(11):837-44. PubMed ID: 19180261
    [Abstract] [Full Text] [Related]

  • 4. Certolizumab pegol for the management of Crohn's disease in adults.
    Rivkin A.
    Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW, Bickston SJ.
    Cochrane Database Syst Rev; 2008 Jan 23; (1):CD006893. PubMed ID: 18254120
    [Abstract] [Full Text] [Related]

  • 7. Certolizumab pegol: in Crohn's disease.
    Blick SK, Curran MP.
    BioDrugs; 2007 Jan 23; 21(3):195-201; discussion 202-3. PubMed ID: 17516714
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Optimizing the use of tumour necrosis factor inhibitors in Crohn's disease: a practical approach.
    Etchevers MJ, Ordás I, Ricart E.
    Drugs; 2010 Jan 23; 70(2):109-20. PubMed ID: 20108987
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months.
    Lichtenstein GR, Thomsen OØ, Schreiber S, Lawrance IC, Hanauer SB, Bloomfield R, Sandborn WJ, Precise 3 Study Investigators.
    Clin Gastroenterol Hepatol; 2010 Jul 23; 8(7):600-9. PubMed ID: 20117244
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of pharmacokinetics and pharmacodynamics and clinical efficacy of certolizumab pegol for Crohn's disease.
    Tun GS, Lobo AJ.
    Expert Opin Drug Metab Toxicol; 2015 Feb 23; 11(2):317-27. PubMed ID: 25586216
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study.
    Winter TA, Wright J, Ghosh S, Jahnsen J, Innes A, Round P.
    Aliment Pharmacol Ther; 2004 Dec 23; 20(11-12):1337-46. PubMed ID: 15606396
    [Abstract] [Full Text] [Related]

  • 18. Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: a real-life multicenter experience of compassionate use.
    Danese S, Mocciaro F, Guidi L, Scribano ML, Comberlato M, Annese V, Colombo E, Stefanelli T, Marzo M, Vangeli M, Pulitano' R, Manca A, Armuzzi A, Malesci A, Prantera C, Cottone M.
    Inflamm Bowel Dis; 2008 Aug 23; 14(8):1168-70. PubMed ID: 18357580
    [No Abstract] [Full Text] [Related]

  • 19. Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol.
    Pasut G.
    BioDrugs; 2014 Apr 23; 28 Suppl 1():S15-23. PubMed ID: 24687235
    [Abstract] [Full Text] [Related]

  • 20. Certolizumab pegol for the treatment of Crohn's disease.
    Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S, PRECISE 1 Study Investigators.
    N Engl J Med; 2007 Jul 19; 357(3):228-38. PubMed ID: 17634458
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.